<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Aminoglycosides: systemic; Pseudomonas aeruginosa infections; Gentamicin; Amikacin; Tobramycin; Neomycin; Bowel: sterilisation; Hepatic encephalopathy; Endocarditis" /><meta name="IX" content="Aminoglycosides: systemic; Pseudomonas aeruginosa infections; Gentamicin; Amikacin; Tobramycin; Neomycin; Bowel: sterilisation; Hepatic encephalopathy; Endocarditis" /><title>5.1.4 Aminoglycosides: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP3465-aminoglycosides.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP3465-aminoglycosides.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP3465-aminoglycosides.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP3253-infections.htm">5 Infections</a> &gt; <a href="PHP3256-antibacterial-drugs.htm">5.1 Antibacterial drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP3463-tigecycline.htm" title="Previous: TIGECYCLINE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP3478-gentamicin.htm" title="Next: GENTAMICIN">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1><span>5.1.4 </span>Aminoglycosides</h1><?highlighter on?><div id="pC" class="jN"><p>These include amikacin, gentamicin, neomycin, streptomycin, and tobramycin. All are bactericidal and active against some Gram-positive and many Gram-negative organisms. Amikacin, gentamicin, and tobramycin are also active against <em>Pseudomonas aeruginosa</em>; streptomycin is active against <em>Mycobacterium tuberculosis </em>and is now almost entirely reserved for tuberculosis (<a title=" Antituberculous drugs" href="PHP3588-antituberculosis-drugs.htm">section 5.1.9</a>).</p> <p>The aminoglycosides are not absorbed from the gut (although there is a risk of absorption in inflammatory bowel disease and liver failure) and must therefore be given by injection for systemic infections.</p> <p>The important side-effects of aminoglycosides are ototoxicity and nephrotoxicity; they occur most commonly in the elderly and in patients with renal failure.</p> <p><strong>Gentamicin</strong> is the aminoglycoside of choice in the UK and is used widely for the treatment of serious infections. It has a broad spectrum but is inactive against anaerobes and has poor activity against haemolytic streptococci and pneumococci. When used for the ‘blind’ therapy of undiagnosed serious infections it is usually given in conjunction with a penicillin or metronidazole (or both). Gentamicin is used together with another antibiotic for the treatment of endocarditis (see below and Table 1, <a title="sub-topic: Cardiovascular system" href="PHP3260-cardiovascular-system.htm">section 5.1</a>).</p> <p>Loading and maintenance doses of gentamicin may be calculated on the basis of the patient's weight and renal function (e.g. using a nomogram); adjustments are then made according to serum-gentamicin concentrations. High doses are occasionally indicated for serious infections, especially in the neonate, in the patient with cystic fibrosis, or in the immunocompromised patient. Whenever possible treatment should not exceed 7 days.</p> <p><strong>Amikacin</strong> is more stable than gentamicin to enzyme inactivation. Amikacin is used in the treatment of serious infections caused by gentamicin-resistant Gram-negative bacilli.</p> <p><strong>Tobramycin</strong> has similar activity to gentamicin. It is slightly more active against <em>Ps. aeruginosa</em> but shows less activity against certain other Gram-negative bacteria. Tobramycin can be administered by nebuliser or by inhalation of powder on a cyclical basis (28 days of tobramycin followed by a 28–day tobramycin-free interval) for the treatment of chronic pulmonary <em>Ps. aeruginosa</em> infection in cystic fibrosis; however, resistance may develop and some patients do not respond to treatment. </p> <p id="PHP3466"><strong>Neomycin</strong> is too toxic for parenteral administration and can only be used for infections of the skin or mucous membranes or to reduce the bacterial population of the colon prior to bowel surgery or in hepatic failure. Oral administration may lead to malabsorption. Small amounts of neomycin may be absorbed from the gut in patients with hepatic failure and, as these patients may also be uraemic, cumulation may occur with resultant ototoxicity.</p> <div id="PHP3467"><h2>Endocarditis</h2><p><strong>Gentamicin</strong> is used in combination with other antibiotics for the treatment of bacterial endocarditis (Table 1, <a title="sub-topic: Cardiovascular system" href="PHP3260-cardiovascular-system.htm">section 5.1</a>). Serum-gentamicin concentration should be determined twice each week (more often in renal impairment). <strong>Streptomycin</strong> may be used as an alternative in gentamicin-resistant enterococcal endocarditis.</p></div> <div id="PHP3468"><h2>Once daily dosage</h2><p><em>Once daily administration</em> of aminoglycosides is more convenient, provides adequate serum concentrations, and in many cases has largely superseded <em>multiple daily dose regimens</em> (given in 2–3 divided doses during the 24 hours). Local guidelines on dosage and serum concentrations should be consulted. A once-daily, high-dose regimen of an aminoglycoside should be avoided in patients with endocarditis, burns of more than 20% of the total body surface area, or creatinine clearance less than 20 mL/minute. There is insufficient evidence to recommend a once daily, high-dose regimen of an aminoglycoside in pregnancy. </p></div> <div id="PHP3470"><h2>Serum concentrations</h2><p>Serum concentration monitoring avoids both excessive and subtherapeutic concentrations thus preventing toxicity and ensuring efficacy. Serum-aminoglycoside concentrations should be measured in all patients receiving parenteral aminoglycosides, and <strong>must</strong> be determined in the elderly, in obesity, and in cystic fibrosis, <em>or</em> if high doses are being given, <em>or</em> if there is renal impairment.</p><p>In patients with normal renal function, aminoglycoside concentrations should be measured after 3 or 4 doses of a multiple daily dose regimen; patients with renal impairment may require earlier and more frequent measurement of aminoglycoside concentration.</p><p>For multiple daily dose regimens, blood samples should be taken approximately 1 hour after intramuscular or intravenous administration (‘peak’ concentration) and also just before the next dose (‘trough’ concentration). If the pre-dose (‘trough’) concentration is high, the interval between doses must be increased. If the post-dose (‘peak’) concentration is high, the dose must be decreased. For once daily dose regimens, consult local guidelines on serum concentration monitoring.</p></div> <div id="PHP3471"><h2>Cautions</h2><p>The main side-effects of the aminoglycosides are dose-related, therefore, care must be taken with dosage, and, whenever possible, parenteral treatment should not exceed 7 days. Renal function should be assessed before starting an aminoglycoside and during treatment. If possible, dehydration should be corrected before starting an aminoglycoside. Auditory and vestibular function should also be monitored during treatment. In order to optimise the dose and avoid toxicity, serum-aminoglycoside concentrations should be monitored in patients receiving parenteral aminoglycosides (see also Serum Concentrations). Ototoxicity and nephrotoxicity occur most commonly in the elderly; therefore, monitoring is particularly important in these patients, who may require reduced doses.</p><p>Aminoglycosides should be used with caution in those with conditions characterised by muscular weakness (avoid in myasthenia gravis). Aminoglycosides should preferably not be given with potentially ototoxic diuretics (e.g. furosemide); if concurrent use is unavoidable administration of the aminoglycoside and of the diuretic should be separated by as long a period as practicable. <strong>Interactions</strong>: Appendix 1 (aminoglycosides)</p></div> <div id="PHP3472"><h2>Contra-indications</h2><p>Aminoglycosides may impair neuromuscular transmission and should not be given to patients with myasthenia gravis</p></div> <div id="PHP3473"><h2>Renal impairment</h2><p>Excretion of aminoglycosides is principally via the kidney and accumulation occurs in renal impairment. Ototoxicity and nephrotoxicity occur commonly in patients with renal failure. If there is impairment of renal function, the interval between doses must be increased; if the renal impairment is severe, the dose itself should be reduced as well. Serum-aminoglycoside concentrations <strong>must</strong> be monitored in patients with renal impairment, see Serum Concentrations above; renal, auditory, and vestibular function should also be monitored. A once-daily, high-dose regimen of an aminoglycoside should be avoided in patients with a creatinine clearance less than 20 mL/minute.</p></div> <div id="PHP3474"><h2>Pregnancy</h2><p>There is a risk of auditory or vestibular nerve damage in the infant when aminoglycosides are used in the second and third trimesters of pregnancy. The risk is greatest with streptomycin (<a title="BNF:monograph: STREPTOMYCIN" href="PHP3636-streptomycin.htm">section 5.1.9</a>). The risk is probably very small with gentamicin and tobramycin, but their use should be avoided unless essential (if given, serum-aminoglycoside concentration monitoring is essential).</p></div> <div id="PHP3475"><h2>Side-effects</h2><p>The important side-effects of the aminoglycosides are nephrotoxicity and irreversible ototoxicity (including vestibular and auditory damage). Rash occurs commonly with streptomycin, but less frequently with the other aminoglycosides. Rare side-effects include nausea, vomiting, antibiotic-associated colitis, peripheral neuropathy, electrolyte disturbances (notably hypomagnesaemia on prolonged therapy, but also hypocalcaemia and hypokalaemia), and stomatitis. Side-effects reported very rarely include blood disorders and CNS effects (including headache, encephalopathy, and convulsions). Aminoglycosides may impair neuromuscular transmission; large doses given during surgery have been responsible for a transient myasthenic syndrome in patients with normal neuromuscular function.</p></div> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP3478-gentamicin"><a href="PHP3478-gentamicin.htm" title="GENTAMICIN">GENTAMICIN</a></li><li id="_PHP3486-amikacin"><a href="PHP3486-amikacin.htm" title="AMIKACIN">AMIKACIN</a></li><li id="_PHP3489-neomycin-sulfate"><a href="PHP3489-neomycin-sulfate.htm" title="NEOMYCIN SULFATE">NEOMYCIN SULFATE</a></li><li id="_PHP3492-tobramycin"><a href="PHP3492-tobramycin.htm" title="TOBRAMYCIN">TOBRAMYCIN</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP3463-tigecycline.htm">Previous: TIGECYCLINE</a> | <a class="top" href="PHP3465-aminoglycosides.htm#">Top</a> | <a accesskey="]" href="PHP3478-gentamicin.htm">Next: GENTAMICIN</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>